Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tranexamic Acid for Craniofacial Surgery

This study has been terminated.
(Study dose changed based on recent publications)
Information provided by (Responsible Party):
University of Pittsburgh Identifier:
First received: July 23, 2008
Last updated: June 25, 2013
Last verified: June 2013

Surgical procedures for the correction of craniofacial deformities result in unavoidable and significant blood loss in small children and infants. Patients may experience blood losses that exceed one to two blood volumes. In an effort to reduce our transfusion requirements, we have introduced tranexamic acid into our practice. However, the benefit of tranexamic acid in pediatric craniofacial surgery has not yet been reported. We hypothesize that the intraoperative use of tranexamic acid in pediatric patients presenting for craniofacial reconstructions will reduce blood loss and allogeneic transfusion requirements.

This is a randomized, blinded, prospective study that will investigate the potential benefit of tranexamic acid to reduce the intraoperative bleeding and blood transfusions in pediatric patients undergoing craniofacial surgeries. An initial dose of 100 mg/kg tranexamic acid (Cyclokapron 100mg/ml) or an equal volume of a placebo will be administered over 15 minutes after the induction of anesthesia and before the skin incision. A maintenance infusion of 10 mg/kg/hr of tranexamic acid or equal volume of a placebo will be started upon completion of the initial dose and will be continued until skin closure. The primary outcome will include the reduction in the total volume of allogeneic erythrocytes, fresh frozen plasma, and cryoprecipitate transfused in the peri operative period (intraoperative and postoperative) and the number of patients that remain transfusion free. Secondary outcomes will include changes in fibrinogen values, TEG, and clinical assessment of the surgical field.

Condition Intervention Phase
Cranial Vault Surgery for Craniosynostosis
Drug: Tranexamic acid
Drug: saline
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Tranexamic Acid for the Reduction of Allogeneic Blood Exposure in Infants and Children Having Craniofacial Surgery

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Total volume (ml/kg) of allogeneic blood exposure [ Time Frame: intraoperative and postoperative (24 hr) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Effect of tranexamic acid on PT,PTT, PLT, fibrinogen, and TEG [ Time Frame: 24 hr ] [ Designated as safety issue: No ]
  • Thromboembolic events [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]

Enrollment: 16
Study Start Date: July 2008
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Tranexamic acid (100 mg/kg load, 10 mg/kg/hr)
Drug: Tranexamic acid
100 mg/kg load, then 10 mg/kg/hr
Placebo Comparator: 2
Drug: saline


Ages Eligible for Study:   6 Months to 18 Years   (Child, Adult)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

The inclusion of the patients will depend on the following criteria:

  1. All pediatric patients scheduled for primary or secondary repair of craniosynostosis with a frontal orbital advancement, or cranial vault reconstruction.
  2. Patients will be between the ages of 6 months and 18 years old.
  3. They will be > than 5 kg.
  4. All subjects being evaluated in the Craniofacial Clinic for primary or secondary repair of craniosynostosis will potentially be included in the study. Prior to inclusion in the study potential participants will be screened by history and laboratory data. The laboratory data will include a complete blood count, PT, PTT, type and cross, factor V leiden, anticardiolipin antibody, and lupus anticoagulant. The history will be obtained from the parents or current care takers. The medical records may be reviewed if there is a need for clarification.

Exclusion Criteria:

Patients that will be excluded from the study include the following:

  1. Familial or personal coagulopathy risk-factor V leiden, anticardiolipin antibody, and lupus anticoagulant
  2. Abnormal PT, PTT, Platelet count. or closing time. All patients presenting for craniofacial surgery have preoperative blood work performed which includes a type and screen, HCT, PLT, PT, PTT, and closing time. Patients who have abnormalities detected in their coagulation profile proceed on to a complete hematologic evaluation that includes an evaluation for Von Willebrand's Disease.
  3. History of thrombotic episodes in the patient
  4. Renal failure or hepatic failure.
  5. Infants less than 5 kg
  6. Age < 6 months or > 18 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00722436

United States, Pennsylvania
The Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
  More Information

Responsible Party: University of Pittsburgh Identifier: NCT00722436     History of Changes
Other Study ID Numbers: PRO07120134 
Study First Received: July 23, 2008
Last Updated: June 25, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
craniosynostosis antifibrinolytics transfusion tranexamic acid

Additional relevant MeSH terms:
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Craniofacial Abnormalities
Musculoskeletal Abnormalities
Congenital Abnormalities
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Coagulants processed this record on January 18, 2017